Want to see PRPH full AI Analyst Report?
PRPH Stock Chart & Stats
$0.02
<$0.01(4.95%)
At close: 4:00 PM EDT
$0.02
<$0.01(4.95%)
Day’s Range― - ―
52-Week Range$0.01 - $6.66
Previous CloseN/A
Volume53.96K
Average Volume (3M)222.31K
Market Cap
$285.39K
Enterprise Value$10.39
Total Cash (Recent Filing)$20.00K
Total Debt (Recent Filing)$9.12M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.44%
Share Statistics
EPS (TTM)-3.12
Shares Outstanding18,120,030
10 Day Avg. Volume98,765
30 Day Avg. Volume222,305
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.88
P/FCF Ratio-0.46
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.4
Revenue Forecast (FY)$41.69M
Bulls Say, Bears Say
Bulls Say
Business Model BreadthProPhase Labs operates across consumer products and diagnostic laboratory services, giving it two distinct avenues for revenue generation. This breadth can support strategic flexibility over the next several months, although performance still depends on rebuilding activity in both areas.
Loss ImprovementThe improvement from the exceptionally large 2024 net loss indicates some movement away from the worst level of earnings deterioration. While results remain deeply unprofitable, continued improvement could provide a foundation for stabilization if revenue and margins recover.
Liquidity FinancingThe financing supplied approximately $1.02 million of net cash, providing near-term liquidity for operations and financial commitments. That funding may give management additional time to execute its business plans, though the secured structure and repayment terms add constraints.
Bears Say
Revenue CollapseThe steep and continuing revenue contraction shows that the company’s current operating base is much smaller than in earlier periods. Sustained low sales reduce scale benefits, weaken the ability to cover fixed costs, and make a durable return to profitability more difficult.
Deep Operating LossesExtremely negative operating and net margins indicate that the present cost structure is far too large for the revenue base. Unless revenue expands materially or expenses are reduced, ongoing losses will continue consuming resources and limit investment in future growth.
Cash Burn And Negative EquityHeavy operating and free-cash-flow losses are eroding financial resilience, while negative stockholders’ equity leaves little balance-sheet cushion. This combination can restrict strategic flexibility, increase reliance on external funding, and heighten refinancing or solvency pressure.
Prophase Labs News
PRPH FAQ
What was Prophase Labs’s price range in the past 12 months?
Prophase Labs lowest stock price was $0.01 and its highest was $6.66 in the past 12 months.
What is Prophase Labs’s market cap?
Prophase Labs’s market cap is $285.39K.
When is Prophase Labs’s upcoming earnings report date?
Prophase Labs’s upcoming earnings report date is Nov 05, 2026 which is in 53 days.
How were Prophase Labs’s earnings last quarter?
Prophase Labs released its earnings results on Aug 06, 2026. The company reported -$0.218 earnings per share for the quarter.
Is Prophase Labs overvalued?
According to Wall Street analysts Prophase Labs’s price is currently Overvalued.
Does Prophase Labs pay dividends?
Prophase Labs pays a Quarterly dividend of $0.3 which represents an annual dividend yield of 1.44%. See more information on Prophase Labs dividends here
What is Prophase Labs’s EPS estimate?
Prophase Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prophase Labs have?
Prophase Labs has 18,120,030 shares outstanding.
What happened to Prophase Labs’s price movement after its last earnings report?
Prophase Labs reported an EPS of -$0.218 in its last earnings report. Following the earnings report the stock price went up 6.977%.
Which hedge fund is a major shareholder of Prophase Labs?
Currently, no hedge funds are holding shares in PRPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prophase Labs
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Technical Analysis
Ownership Overview
―
Insiders
0.12% Mutual Funds
0.47% Other Institutional Investors
99.42% Public Companies and
Individual Investors